Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 -2.50%73 Altman Z-Score is 35.29 as of Jul. 14, 2026, which is 7% below its 10-year median of 37.91. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 928 Biotechnology companies, BioGend Therapeutics Co ranks better than 93.1% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 36.69 is strong.
BioGend Therapeutics Co has a Altman Z-Score of 35.29, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for BioGend Therapeutics Co's Altman Z-Score or its related term are showing as below:
ROCO:6733'
s Altman Z-Score Range Over the Past 10 Years
Min: 14.46 Med: 37.91 Max: 101.53
Current: 36.69
During the past 10 years, BioGend Therapeutics Co's highest Altman Z-Score was 101.53. The lowest was 14.46. And the median was 37.91.
BioGend Therapeutics Co (ROCO:6733) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Altman Z-Score falls into.
BioGend Therapeutics Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
BioGend Therapeutics Co (ROCO:6733) has a Altman Z-Score of 35.29 as of Jul. 14, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioGend Therapeutics Co and its competitors. This is near median its historical median of 37.91. Over the past decade, BioGend Therapeutics Co's Altman Z-Score has ranged from 14.46 to 101.53. According to the industry distribution chart, BioGend Therapeutics Co ranks #64 out of 928 companies in the Biotechnology industry, placing it in the top 6.9%.
Is BioGend Therapeutics Co's Altman Z-Score too high?
BioGend Therapeutics Co's current Altman Z-Score of 35.29 is near median its 10-year median of 37.91. Over the past 10 years, this metric has ranged from a low of 14.46 to a high of 101.53. The Biotechnology industry median Altman Z-Score is 2.69. BioGend Therapeutics Co's value of 35.29 is 1211.9% above this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #64 out of 928 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #64 out of 928 companies for Altman Z-Score. This places BioGend Therapeutics Co in the top 7% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.69. BioGend Therapeutics Co's value of 35.29 is 1211.9% above this benchmark. Historically, BioGend Therapeutics Co's own Altman Z-Score has ranged from 14.46 to 101.53 over the past decade. While the company's 10-year median is 37.91 vs. the industry median of 2.69, BioGend Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.69, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current Altman Z-Score of 35.29 is 1211.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Altman Z-Score is 35.29, which is near median its own 10-year median of 37.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Altman Z-Score is 35.29, which is near median its 10-year median of 37.91 and 1211.9% above the Biotechnology industry median of 2.69. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Altman Z-Score is 35.29 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Altman Z-Score: 35.29 (near median its 10-year median of 37.91)
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
Industry Position: 1211.9% above the Biotechnology median (#64 of 928)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
